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Cerebral vasospasm following subarachnoid hemorrhage: time
for a new world of thought
Abstract
Objective: Delayed cerebral vasospasm has long been recog-nized as an important cause of poor
outcome after an otherwise successful treatment of a ruptured intracranial aneurysm, but it remains a
pathophysiological enigma despite intensive research for more than half a century. Method:
Summarized in this review are highlights of research from North America, Europe and Asia reflecting
recent advances in the understanding of delayed ischemic deficit. Result: It will focus on current
accepted mechanisms and on new frontiers in vasospasm research. Conclusion: A key issue is the
recognition of events other than arterial narrowing such as early brain injury and cortical spreading
depression and of their contribution to overall mortality and morbidity.
Cerebral vasospasm following subarachnoid hemorrhage: time
for a new world of thought
Ryszard M. Pluta, Jacob Hansen-Schwartz, Jens Dreier, Peter Vajkoczy, R. Loch
Macdonald, Shigeru Nishizawa, Hideotoshi Kasuya, George Wellman, Emanuela Keller, Alois
Zauner, Nicholas Dorsch, Joseph Clark, Shigeki Ono, Talat Kiris, Peter LeRoux, and John H.
Zhang
Abstract
Objective—Delayed cerebral vasospasm has long been recognized as an important cause of poor
outcome after an otherwise successful treatment of a ruptured intracranial aneurysm, but it remains
a pathophysiological enigma despite intensive research for more than half a century.
Method—Summarized in this review are highlights of research from North America, Europe and
Asia reflecting recent advances in the understanding of delayed ischemic deficit.
Result—It will focus on current accepted mechanisms and on new frontiers in vasospasm research.
Conclusion—A key issue is the recognition of events other than arterial narrowing such as early
brain injury and cortical spreading depression and of their contribution to overall mortality and
morbidity.
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INTRODUCTION
When persons in good health are suddenly seized with pains in the head, and
straightway are laid down speechless, and breathe with stertor, they die in seven days.
Hippocrates 460–370 BC, Aphorisms on Apoplexy1
Hippocrates’ 2400-year-old description of delayed death probably caused by a ruptured
intracranial aneurysm with subsequent vasospasm is still valid today. Aneurysmal
subarachnoid hemorrhage (SAH) affects about 10 out of 100,000 adults annually, and up to
half of those affected die soon after2; most of the rest are successfully treated surgically and/
or endovascularly. Despite obliterating the offending aneurysm and removing the risk of
rebleeding, up to half of the treated patients develop a syndrome of focal and/or cognitive
deficits due to cerebral vasospasm (delayed ischemic neurological deficit, symptomatic
vasospasm) between the fourth and ninth day after the SAH3. As a result, many die or suffer
permanent morbidity2, and it has been described as the single most important cause of
morbidity and mortality in patients whose ruptured aneurysm is successfully treated4.
Patients require vigilant monitoring and treatment for up to 2 weeks, including invasive
monitoring of blood pressure, cerebral blood flow and metabolism and often complex treatment
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with calcium antagonists, hypertensive drugs, hemodilution and hypervolemia (triple H
therapy), plus risky and often only temporarily effective intra-arterial administration of
vasodilator drugs or balloon angioplasty5. These treatments have been documented in nine
international conferences on cerebral vasospasm (Table 1).
Since the demonstration of arterial narrowing in the syndrome of cerebral vasospasm in
19516 and the further emphasis in 1978 by Weir et al.3, it has been proven that SAH gives rise
to arterial narrowing and in turn ischemia, causing infarction and poor outcome. Most research
into delayed deterioration after SAH has been conducted in concordance with this axiom, with
the goal of interrupting this perceived chain of events. There have been many clinical trials,
but until the arrival of clazosentan, a selective endothelin 1A receptor antagonist, it has not
been possible to reproducibly break this chain. Clazosentan did, however, effectively prevent
and reverse arterial narrowing in one work7, providing what was thought may at last be an
effective treatment. However, the subsequent multi-center CONSCIOUS trial, despite
significant reductions in angiographic vasospasm, failed to show any effect on long-term
outcome.
The axiom has thus been challenged in such a fashion that it amounts to a paradigm shift.
Accumulated evidence suggests that (1) arterial narrowing is not the only cause of delayed
clinical deterioration, (2) arterial narrowing is not necessarily multifactorial but (3) may
actually be an effect of a single factor and finally (4) the entire picture of delayed clinical
deterioration may be multifactorial. These facts should lead to a search for a more
comprehensive and adequate theory that not only can explain observed discrepancies but also
will lead to development of a specific and effective treatment strategy.
In recent years, two major concepts in pre-vasospasm research have developed: early brain
injury and cortical spreading depression. Basic animal works and some clinical observations
have long pointed to the importance of the pre-vasospasm period, with recognition of the
importance of transitory ischemia at the onset of SAH 8, the opening of the blood–brain
barrier9,10, the existence of early arterial narrowing in clinical settings11 and the detection of
cortical spreading ischemia after SAH12. One or more of these events may replace arterial
narrowing as important causes of poor outcomes after SAH13.
PATHOPHYSIOLOGY OF ARTERIAL NARROWING: NEW DEVELOPMENTS
The idea of arterial narrowing has previously been central to understanding the syndrome of
cerebral vasospasm, but as outlined above, a paradigm shift is underway. Even so, the
association of arterial narrowing with delayed ischemic deficits and the fact that reversal of
narrowing by angioplasty can reverse deficits make consideration of pathophysiological events
in cerebral arteries still very relevant, as shown in several reviews. Highlights of recent
developments are presented below.
Hemoglobin
Ferrous hemoglobin released from subarachnoid clot undoubtedly leads to delayed arterial
narrowing by mechanisms, which are multiple and poorly understood. Possibilities include
neuronal apoptosis14, scavenging or decreased production of nitric oxide (NO)15, increased
endothelin 1 levels16, direct oxidative stress on smooth muscle cells13, free radical production
and lipid peroxidation of cell membranes17, modification of potassium and calcium
channels18 and differential up-regulation of genes19,20.
Recent research has focused on oxidative stress as causing or contributing to vasospasm,
possibly via direct activation of calcium channels in smooth muscle cells as well as on
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vasoactive proteins21 or through covalent modification by reactive oxygen species producing
vasoactive molecules. For example, reactive oxygen species may act on arachidonic acid to
produce vasoactive lipids, which in turn may contribute to vessel contraction. The lack of
success of antioxidants such as tirilazad makes non-specific oxidation unlikely22. Other
possible vasoactive compounds are bilirubin oxidation products (Figure 1), synthesized by the
oxidation associated with oxidative stress. However, the location of the oxidations leading to
the production of bilirubin oxidation products is unclear. It could be speculated that lysed blood
cells are phagocytosed by lymphocytes, with resultant heme or bilirubin release after
lysosomatic breakdown. In such a scenario, antioxidants that primarily target membranes
would have relative little effect22.
Oxidative stress in the subarachnoid space has also been reported to activate protein kinase C
and Rho kinase, leading to smooth muscle cell constriction. Rho kinase initiates vascular
contraction through protein kinase Cδ activity (Figure 2), which also induces proliferation and
growth of vascular smooth muscle cells, a possible mechanism for the phenotypic change and
remodeling of vascular smooth muscle seen in vasospasm23. Further support for a
reorganization hypothesis comes from observations of increased β-actin messenger RNA
(mRNA), of structural change in the 3′ untranslated region of β-actin mRNA and of induction
of the embryonal isoform of myosin heavy chain accompanied by a decrease in the expression
of smooth muscle myosin heavy chain in arteries in spasm23. Histological morphometric
analysis also showed an increase in the area of the arterial wall without changes in the number
of nuclei of smooth muscle cells24. Therapy for cerebral vasospasm may thus also need to
address cerebral vascular remodeling.
Endothelin 1
The potent vasoconstricting peptide endothelin 1 was isolated from pig endothelial cells in
198825, and elevated endothelin 1 levels in the cerebrospinal fluid of patients and animals with
vasospasm were soon reported16,26,27. This basic observation was supported by a number of
experimental results. Oxyhemoglobin causes an increase in endothelin 1 synthesis from
endothelial cells28, astrocytes may synthesize endothelin 1 in response to ischemia26 and
leucocytes that have infiltrated the subarachnoid space after SAH may produce endothelin
129. Furthermore, cerebral arteries may become more sensitive to endothelin 1, leading to
increased cerebrovascular tone even in the absence of an increase in endothelin 130. These
findings provided the impetus for trials of endothelin receptor antagonists7. A phase II study
of the endothelin receptor antagonist clazosentan in aneurysmal SAH randomized 413 patients,
well balanced for prognostic factors. Moderate to severe angiographic vasospasm was
significantly reduced in a dose-dependent manner from 66% in the placebo group to 36% in
the high-dose clazosentan group. Despite this reduction, there was no significant effect on
outcome based on the modified Rankin scale at 3 months31. Why this efficacy against
angiographic vasospasm did not translate into improved outcome is a key question and a
fundamental reason for the paradigm shift necessary to produce a more complete understanding
of cerebral vasospasm and delayed deterioration.
Nitric oxide
Inhibition of relaxation can also cause or contribute to arterial narrowing because of the basic
myogenic tone of cerebral arteries. Hence, the fate of NO (a powerful endogenous vasodilator)
has attracted interest. The disappearance of neuronal NO synthase immunoreactivity from
arteries in spasm, endothelial NO synthase dysfunction in cerebral vessels after SAH and the
affinity for NO of the heme moiety in hemoglobin (‘NO sink effect’) suggest a role for NO
depletion in the pathophysiology of arterial narrowing (Figure 3)15. New strategies for NO-
based therapy against vasospasm include gene therapy32,33 preclinical and early clinical trials
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of NO donors administered intra-arterially34, intrathecally35, locally36,37 or
intravenously38.
In terms of genetic predisposition in the NO synthase system, Khurana et al.39 reported that
the endothelial NO synthase T-786C single-nucleotide polymorphism, associated with a
significant reduction in endothelial NO synthase gene promoter activity, was significantly more
common in patients with cerebral vasospasm. Another development in relation to NO synthase
is the statins, which improve endothelial function by up-regulating endothelial NO synthase
expression40. A threefold increase in endothelial NO synthase mRNA, protein and enzymatic
activity has been demonstrated following statin treatment, resulting in an increase in cerebral
blood flow41,42. Statin treatment has attenuated cerebral vasospasm and prevented delayed
ischemic deficits in a murine SAH model40. In a retrospective series, patients who received
statin therapy for at least 1 month before SAH demonstrated an 11-fold decrease in the risk of
developing symptomatic vasospasm after SAH43. In recent prospective, double-blind,
randomized placebo-controlled clinical trials of statins given for 14 days after SAH, the
incidence of symptomatic cerebral vasospasm was significantly reduced in treated
patients44,45.
Membrane pathology
Small diameter cerebral arteries (<200 μm) play important roles in the autoregulation of
cerebral blood flow, matching local blood supply in the brain to neuronal activity (Figure 4)
46. Although angiography, which can assess arteries >1 mm in diameter, has long been the
standard to diagnose vasospasm47, constriction of small cerebral arteries may also contribute
to ischemia after SAH21,48–51.
The concentration of free intracellular Ca2+ ([Ca2+]i), and thus the contractile state of smooth
muscle cells in cerebral resistance arteries, is determined primarily by Ca2+ influx through
voltage-dependent Ca2+ channels52, the open-state probability of which is dictated by the
membrane potential of the smooth muscle cells53. Following SAH, changes have been reported
in the electrical properties of smooth muscle cells of small diameter cerebral arteries leading
to enhanced Ca2+ influx, with vasoconstriction and decreased cerebral blood flow54. Cerebral
arteries from healthy animals express only L-type voltage-dependent Ca2+ channels encoded
by the gene CaV 1.2. Expression of an additional type of voltage-dependent Ca2+ channels (R-
type, CaV 2.3) occurs after SAH, leading to increased Ca2+ channel density, increased Ca2+
influx and vasoconstriction55.
After SAH, calcium entry is further enhanced by membrane depolarization54,56.
Oxyhemoglobin causes suppression of the voltage-dependent K+ channel (KV) current in
cerebral artery smooth muscle cells through a mechanism involving tyrosine kinase-mediated
channel endocytosis55. Decreased activity of large conductance calcium-activated K+
channels may also contribute to membrane depolarization via potential mechanisms, such as
a decrease in Ca2+ spark frequency57 and increased production of the cytochrome P450
metabolite 20-hydroxyarachidonic acid58. This combination of increased voltage-dependent
Ca2+ channel density and membrane depolarization will increase [Ca2+]i and lead to
vasoconstriction. At the same time, decreased sensitivity of voltage-dependent Ca2+ channels
s to L-type Ca2+ channel antagonists55 may limit the utility of agents, such as nimodipine, in
the treatment of arterial narrowing. Targeting voltage-dependent Ca2+ channels and K+
channels in small diameter cerebral arteries may lead to safer and more effective treatments
for SAH.
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NEW FRONTIERS OF CEREBRAL VASOSPASM RESEARCH
Acute and early changes after aneurysmal SAH
One of the most important advances in recent years is the recognition of early brain injury after
SAH, from the impact of the initial bleed and its detrimental effect on patient outcome. The
term early brain injury has only recently been coined and refers to the injury to the brain as a
whole within the first 72 hours after the ictus59, i.e. before the development of vasospasm.
This early brain injury includes an elevation of intracranial pressure, a global reduction of
cerebral blood flow, blood–brain barrier disruption, brain edema and neuronal cell death.
Decreased perfusion pressure after SAH was reported in patients by Nornes8, but its influence
on outcome has only recently been recognized. The initial event of intracranial aneurysm
rupture is the stop flow phenomenon14, with an acute transient global cerebral ischemia, which
may itself be lethal2. When the patient survives, there may be a secondary ischemic insult due
to blood–brain barrier disruption60 progressing to global cerebral edema61 or to delayed
neuronal apoptosis14. Brain edema contributes to a further rise in intracranial pressure13 and
thus a further reduction of cerebral blood flow. The mechanism of blood–brain abrrier
disruption is unclear, but apoptosis affecting the brain and arteries may be involved13,60.
Cortical spreading depression
In experimental works by Dreier et al.62, fluid with a composition similar to the cerebrospinal
fluid after SAH was applied in the subarachnoid space. This induced spreading depolarization
waves over the cortex, which in turn triggered spreading microvascular spasm and spreading
ischemia62, leading to widespread cortical necrosis12. This pathomorphological finding
corresponds with autopsy works of non-operated SAH patients, in which 80% of fatal cases
showed widely scattered triangular, round or laminar ischemic cortical lesions, 13 times more
common than infarcts in the territories of large arteries63,64. In a clinical work of 18 patients
undergoing craniotomy for hematoma evacuation or aneurysm treatment following aneurysmal
SAH65, 13 showed waves of spreading depolarization. In several patients, clusters of spreading
depolarizations occurred at the onset of neurological deterioration, and in some, prolonged
periods of depressed electrocorticographic activity were followed by radiographic evidence of
ischemia. There is thus clinical evidence for the first part of the ‘spreading ischemia theory’
of cortical infarcts after SAH, i.e. association with a cluster of spreading depolarizations (Figure
5). The decisive second part of the hypothesis, that a marked propagating decrease of cortical
blood flow occurs in conjunction with spreading depolarizations and leads to delayed infarcts,
remains open.
It is assumed that breakdown products of erythrocytes in the subarachnoid space induce delayed
neurological deficits after SAH, based on observations that the risk of developing delayed
neurological deficits correlates with the amount of blood in the initial computed axial
tomography scan and that its onset coincides with the time of peak subarachnoid hemolysis in
the primate model of SAH. According to the double hit model (Figure 5), breakdown products
of erythrocytes have four major synergistic pathological effects: They induce chronic
vasospasm of (1) proximal cerebral arteries and (2) the microcirculation; (3) they promote
spreading depolarizations via chronic vasospasm/energy depletion, increase of the baseline
extracellular K+ concentration and endothelin 1 and a decrease of NO; (4) they invert the
coupling between spreading depolarization of the cortex and cerebral blood flow by direct
effects (K+ ↑, NO↓) and indirectly via chronic vasospasm/energy depletion. Consistently with
the double hit model, it was recently shown using subdural electrodes that delayed ischemic
infarcts in SAH patients are preceded and accompanied by clusters of spreading depolarizations
with prolonged depression periods65. There is still no direct evidence of spreading ischemia
in the human brain. Spreading depolarization is an energy-demanding perturbation of brain
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cortical ion homeostasis and energy metabolism; in response to this demand, cerebral blood
flow rises during spreading depolarization under physiological conditions. However, in the
presence of breakdown products of erythrocytes in rats12,62, as well as in the ischemic
penumbra after middle cerebral artery occlusion in mice66, spreading depolarization induces
severe acute microarterial spasm and spreading ischemia, rather than microarterial dilation and
spreading hyperemia. This process is called ‘inverse coupling’12,62. Spreading ischemia is
associated with virtual disappearance of the pial circulation for periods of minutes or hours
and leads to widespread cortical infarcts in these rat experiments12.
TREATMENT OF VASOSPASM
The importance of the therapeutic approach of multimodality treatment is stressed
Delayed neurological deficits after aneurysmal SAH are not caused by one single factor and
therefore cannot be expected to be prevented or reversed by a single treatment such as
clazosentan. Clinical trials have shown promising results for the cisternal placement of
controlled-release nicardipine or papaverine pellets, for intravenous magnesium sulfate, for
oral pravastatin or simvastatin, for lumbar cerebrospinal fluid drainage and for lamina
terminalis fenestration67–69. There have been reports on variations of the head shaking
technique with cisternal lavage, enoxaparin, cervical sympathetic block, aortic balloon
counterpulsation or partial blockage and nitroglycerine patches5. Many of these works showed
significantly reduced delayed neurological deficits and/or lower mortality.
Systemic: fasudil and multimodal therapy
Intra-arterial fasudil hydrochloride (a Rho-kinase inhibitor) is part of the multimodal therapy
after SAH in Japan70, along with cisternal urokinase injection71, drainage of subarachnoid
clots69 and strict maintenance of general conditions. The result of multimodal treatment with
fasudil when compared with patients without multimodal therapy was a decrease in incidence
of vasospasm from 57 to 37% with subsequent reduced mortality and improved outcome.
Topical: nicardipine
Clinical trials have tested the efficacy against vasospasm of local prolonged-release
nicardipine-loaded polymers72,73 implanted at the time of aneurysm clipping into the basal
cisterns close to the proximal arteries, with the drug being released over 14 days. In the first
work, arterial narrowing was completely prevented in arteries surrounded by thick clot. The
second work confirmed reductions in vasospasm (73% control versus 7% nicardipine-loaded
polymers) and delayed ischemic lesions (47% control versus 14% nicardipine), and the
outcome was significantly better. This polymer-based drug-delivery system offers a new and
promising treatment approach. However, the lack of drug penetration to areas covered by blood
clot is a potential limitation, needing further elucidation for the routine clinical setting.
Intra-arterial: nicardipine/verapamil
Safer endovascular treatments for severe refractory arterial narrowing are now available74. In
one series of 350 SAH patients, 47 developed severe clinical vasospasm requiring endovascular
therapy, including 175 intra-arterial injections of nicardipine (average dose, 6.0 mg; maximum,
22 mg per patient) or verapamil (8.0 mg per vessel, maximum 16 mg per patient) and 49 balloon
angioplasties. There was significant improvement after the intra-arterial drug treatment, lasting
for 24–48 hours, while balloon angioplasty, mostly (49%) for middle cerebral arteries, was
more effective for proximal artery spasm. There were no complications from the angioplasty
itself (A Zauner, unpublished data).
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CONCLUSION
While our understanding of the pathophysiology of delayed vasospasm has progressed
significantly, this knowledge has not been translated into clinically effective treatment.
Possible sources of this mismatch include the multifactorial nature of the disease, the use of
inadequate animal SAH models (e.g. models that create SAH but do not alter intracranial
pressure), the lack of randomization or blinded assessment in many preclinical and some
clinical works, underpowered experimental and clinical works, the lack of a priori identified
inclusion/exclusion criteria and bias toward publication of positive but not negative
findings75. The results of the phase II international clazosentan study support the concept that
linking outcome solely to delayed vasospasm is an oversimplification, focusing attention on
vasospasm rather than on patients’ well-being (RL Macdonald, unpublished data). This work
opens up the question of why the prevention of vasospasm did not translate into improved
outcome. It seems clear now that research must focus more on the acute subacute, delayed and
late events after aneurysmal SAH and their influence on outcome.
These new developments in the understanding of the pathophysiology of SAH and vasospasm
and advances in the treatment, as well as controversies around both pathophysiology and
treatment, make it mandatory to ‘spread the word’ among researchers and clinicians that a
widening of interest from delayed arterial narrowing to other SAH-evoked events is now
essential. Research on the relationship between all post-hemorrhage events and their
contribution to outcome should hasten the development of effective treatment for vasospasm
and other events. A crucial element will be the use of improved animal models to help elucidate
the contributions of the various mechanisms discussed above, as well as others not specifically
addressed in this work such as thromboembolism76 platelet activation or inflammation, to
delayed vasospasm or deterioration after aneurysmal SAH.
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Figure 1.
A putative pathway for the production of bilirubin-oxidized fragments (BOXes) from blood
present post-SAH. Key steps are the liberation of heme from blood and oxidation from free
radicals. The dotted line between the heme and oxidation of bilirubin is a pathway for the
production of BOXes that has not yet been demonstrated
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Figure 2.
Relations among Rho kinase, Rho A, PKCI′ and PKCI± for the regulation of myosin and actin
in the contraction and relaxation of vascular smooth muscle cells. Rho kinase and Rho A
activate myosin light chain (MLC) phosphorylation directly. Rho kinase and Rho A inhibit
MLC phosphatase, resulting in long lasting MLC phosphorylation. They also activate PKCI′,
which enhances the contraction of vascular smooth muscle cells. PKCI± independently
activates the contraction of vascular smooth muscle cells. Caldesmon is an actin-side regulatory
protein acting on the detaching between actin and MLC and relaxation of the vascular smooth
muscle cells. PKCI′ inhibits the activity of caldesmon through phosphorylates of caldesmon,
which causes long lasting interaction between actin and MLC. MLC, myosin light chain;
MLCK, myosin light chain kinase; P, phosphorylation; PKC, protein kinase C
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Figure 3.
Signal transduction for nitric oxide (NO) and endothelin 1 (ET-1). These are antagonistic
regulators of cerebral blood flow, released from endothelial cells in response to changes in the
shear stress, transmural pressure, concentration of CO2 and O2, ischemia or presence of
hemoglobin. NO (vasodilator) and ET-1 (vasoconstrictor) regulate blood vessel tension via
smooth muscle cells. NO, due to its high affinity to the heme moiety (1000 times higher than
oxygen), stimulates guany(ly)l cyclase, leading to an increase of 3,5′ cyclic guanosine
monophosphate and dephosphorylation of MLCs, smooth muscle cell hyperpolarization and
closure of calcium channels resulting in vasodilation and an increase of blood flow. ET-1 is a
product of several post-translational modifications of pre-pro-ET-1 and big ET-1. It acts on
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smooth muscles via two types of receptors: ETA, present mostly on smooth muscle cells, whose
stimulation leads to smooth muscle constriction (paracrine action), and ETB, present mostly
on endothelial cells, stimulation of which leads to an increased NO release and to smooth
muscle relaxation (endocrine action). ET-1 stimulation of the ETA receptor leads to the
formation of diacylglycerol and inositol 1,4,5-triphosphate, which in turn increases the
concentration of intracellular calcium directly or via protein kinase C, resulting in
vasoconstriction and decrease of blood flow
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Figure 4.
Potential mechanisms of increased vascular smooth muscle intracellular Ca2+ and enhanced
contraction of cerebral artery myocytes following SAH. Enhanced Ca2+ influx through voltage-
dependent Ca2+ channels (VDCCs) may result from a combination of increased VDCC
expression (L- and R-type) and increased VDCC activity due to membrane depolarization.
Mechanisms contributing to depolarization include oxyhemoglobin-induced internalization of
voltage-dependent (KV) K+ channels and decreased activity of large-conductance Ca2+ -
activated (BK) K+ channels due to inhibition of Ca2+ sparks and/or increased levels of the
cytochrome P450 metabolite 20-hydroxyeicosatetraenoic acid
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Figure 5.
Double-hit model of delayed ischemic neurological deficits after SAH based on Dreier et al.
12. The two hits on the brain parenchyma consist of acutely triggered microvascular spasm in
response to spreading depolarizations, superimposed on chronic vasospasm
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